Member Info for liquid1

Big trades Toronto before close

Agnico Eagle Announces Exploration Joint Venture in Colombia with Newmont
Investing News Network - September 29th, 2020
Agnico Eagle Mines announced today that it has formed an exploration joint venture in Colombia with Newmont.





Agnico Eagle Mines Limited (NYSE: AEM, TSX: AEM) (“Agnico Eagle”) announced today that it has formed an Exploration Joint Venture (the “Joint Venture”) in Colombia with Newmont Corporation (NYSE: NEM, TSX: NGT) (“Newmont”). The 50-50 Joint Venture, which will be operated by Agnico Eagle, will explore the Anza project and seek other prospective gold targets of district-scale potential in Colombia .

“The Anza project is well located within the Mid-Cauca belt in Colombia which hosts several world class gold deposits. Historical work on the project indicates the potential for various styles of mineralization, including porphyry, epithermal and VMS”, said Guy Gosselin , Agnico Eagle’s Senior Vice-President, Exploration. “Agnico Eagle has been actively looking at Colombia for some time, and this low-cost entry is consistent with our exploration strategy and existing investment in Royal Road Minerals. We look forward to working with our Joint Venture partner Newmont to advance the Anza project”, added Mr. Gosselin.

The Anza project is a gold exploration project, comprising exploration contracts and applications totaling approximately 200 km 2 located in the Mid-Cauca belt in Colombia . The project is 50 km west of Medellin and 60 km south from Zijin Mining’s Buritica operation. More information on the Anza project and Newmont’s previously announced Exploration Agreement with Orosur Mining Inc. (“Orosur”) with respect to the Anza project can be found in Orosur’s news release dated September 10, 2018 .

Agnico Eagle will sole fund the Joint Venture until expenditures equal Newmont’s previous investment in the Anza project (approximately $2.9 million ), which is expected to be achieved in the next 12 months. Thereafter the parties will continue funding on a 50-50 basis.

About Agnico Eagle

Agnico Eagle is a senior Canadian gold mining company that has produced precious metals since 1957. Its operating mines are located in Canada , Finland and Mexico , with exploration and development activities in each of these countries as well as in the United States and Sweden . Agnico Eagle and its shareholders have full exposure to gold prices due to its long-standing policy of no forward gold sales. Agnico Eagle has declared a cash dividend every year since 1983.

https://investingnews.com/news/gold-investing/agnico-eagle-announces-exploration-joint-venture-in-colombia-with-newmont/

To now have two of the world's top 10 gold miners (combined production of over 7.5 million ounces per year) investing in our project is testament to its potential and we look forward to an eventful year,” said Orosur chief executive Brad George.

Update on Results and Notice of Suspension



Malvern International plc (AIM: MLVN) announces that it is not going to be able to publish its Annual Report and Accounts for the year ended 31 December 2019 (the "Accounts") as required by Rule 19 of the AIM Rules for Companies by the extended deadline of 30 September 2020. Consequently, the Company's shares will be suspended temporarily from trading on AIM as of 7.30am on Thursday 1 October 2020, pending publication of the Accounts. The Directors are endeavouring to complete the procedures required for audit completion and will publish the Accounts in the week commencing 5 October 2020.



In addition, the Company announces that it is utilising the one month extension to the reporting deadline for its interim results for the six months ended 30 June 2020 ("Interim Results") as offered by the Inside AIM published on 9 June 2020. Therefore, the new deadline for publication of the Interim Results is 31 October 2020.

The Company has applied for and received an extension to the period allowed for it to publish the 2019 Accounts which now expires on 30 September 2020.

6. Current trading and prospects



There has been no material change in the trading of the Company since the trading update given the announcement of 20 May 2020. The London school remains closed but bookings are being taken for September 2020. The Singapore school remains closed to students but as of 29 June 2020 it will be able to reopen although its operating capacity will be restricted to 60% of its maximum. A review of operations in Singapore is expected to be undertaken following the appointment of new CEO, Richard Mace (see paragraph 9 below).

Since the announcement of 20 May 2020, the Company has continue to utilise the UK Government furlough scheme and it has secured a government support loan of £100,000.

Due to the time taken arranging the Fundraising, work on the Company's audited results for the year ended 31 December 2019 (the "2019 Accounts") has been delayed. The Company has applied for and received an extension to the period allowed for it to publish the 2019 Accounts which now expires on 30 September 2020. The Company now expects to announce its results and publish the 2019 Accounts in the first half of August.

https://www.investegate.co.uk/malvern-inter--plc--mlvn-/rns/issue-of-equity/202006251412591211R/

Drifty69

Malvern International is a global learning and skills development partner preparing learners to meet the demands of a professional life.

So us Malvern going to gain from UK gov?

Prime minister announces ‘Lifetime Skills Guarantee’
Yesterday the Prime Minister announced huge changes to the adult education system in England to help boost the post-Covid economy.

One of the key points raised was a new “lifetime skills guarantee” that would offer a fully funded college course to all people over 18 in England without an A-level or equivalent qualification. The commitment will be paid for under an already-announced £2.5bn boost to England’s National Skills Fund coming into effect in April 2021.

https://www.nsar.co.uk/2020/09/prime-minster-announces-lifetime-skills-guarantee/

Last year they came in the evening:

28 Jun 2019 5:11 pm
RNS
Factsheet Malvern Inter. PLC (MLVN) Final Results
11:38 am
RNS
Factsheet Malvern Inter. PLC (MLVN) Adjournment of AGM
7:00 am
RNS
Factsheet Malvern Inter. PLC (MLVN) Update on Results
—————————/—————-
Malvern had expected to announce its results for the year ended 31 December 2018 yesterday. The Company continues to endeavour to finalise these results as soon as possible and will make a further announcement in due course.



https://www.investegate.co.uk/malvern-inter--plc--mlvn-/rns/update-on-results/201906280700077411D/

Question to CEO?
With 3 and half months until the end of the year, do you have any milestones that you will be announcing that will generate further highs in the stock price.

Duncan, yes ' we have just finished a trial in IBS, then explains the size of the market and that the current drugs don't really work because of the side effects and he is hopeful that they have.

Results out later this month/early next month.

Wow, he will know the results generally and this confirms that he sees this announcement as a milestone that will generate further highs in the stock price.

A few weeks ago:

sp hit 148p, then dropped to 105p, and then went back up to over 148p to 160p.

Hope news this week sends this much much higher!

ValiRx confirms VAL201 shows potential for a safe prostate cancer drug with a 55% response rate
September 28, 2020

https://www.sharebuyers.co.uk/shares/val201-shows-potential-for-safe-prostate-cancer-drug/

Current Mcap only 31m for Breaking Cancer treatment news!

OMG, if they pull this through on incurable stage3/4 cases, then that would be an incredible result!

https://clinicaltrials.gov/ct2/history/NCT02280317?A=1&B=13&C=Side-by-Side#StudyPageTop

Eligibility:
Stage III Prostate Carcinoma
Stage IV Prostate Carcinoma

Inclusion criteria:
-Specific Inclusion Criteria for Patients with Prostate Cancer
-Patients with incurable, locally advanced or metastatic prostate cancer where a policy of intermittent hormone therapy has been decided. Who have specific clinical parameters.
-Specific Inclusion Criteria for Patients with Other Advanced Solid Tumours
-Patients with histologically and/or cytologically confirmed advanced solid tumour for whom no standard effective therapy is available and a rationale for use of VAL201 exists.
Patients with incurable, locally advanced or metastatic prostate cancer where a policy of intermittent hormone therapy has been decided. These patients must also have the following:
-Rising PSA on three samples (once non-castrate levels established); each over 2 weeks apart, with the last two values being greater than 2 ng/mL. Higher than and at least 25% over the nadir.
-Absent or very mild prostate cancer-related symptoms.
-No plans for any therapy for prostate cancer in the next two months.

https://www.brrmedia.co.uk/broadcasts/5f042b7a4e934f0a0e3eba3d/valirx-strategy-update

CEO talks about VAL201. The most important news to come. 2.30 minutes before the end.
Coming before the end of September

Consolidation complete today!

Onwards and upwards next week

They want 56.8p

ValiRx reports that the trial thus far has met all the primary and secondary endpoints. The safety and tolerability results continue to be acceptable and further evidence of the compound's positive effect in reducing the progress of prostate cancer has been witnessed. The data from the trial is currently being collated for examination by independent third party experts. The approval of the amendment further validates the Company's clinical development throughout VAL201's First-in-Human Trial. Further information connected to the data and the results and findings from the trial will form the basis of a report outlining the compound's clinical profile and behaviour, which will be published in due course.

UPDATE ON VAL201 CLINICAL TRIAL

"Positive Effect on Cancer Patients"

"Evidence revealed of decrease in prostate cancer biomarker PSA, related to dosing with VAL201"

London, UK., 10 December 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is proud to announce that independent analysis of VAL201 data shows a statistically significant dose dependant response in the reduction of PSA correlated to time on the Phase l/ll clinical trial, involving patients with hormone-sensitive and hormone-resistant prostate cancer.

This represents an initial formal statistical analysis of the VAL201 clinical data conducted by Dr Wilson Caparrós-Wanderley, an independent statistical consultant. This was undertaken using a non-parametric approach - both the well-established 'Friedman Test' (developed by M. Friedman in 1937) and the most up-to-date statistical method, 'Repeated Measures Multiple Correlation Analysis' (refined by Bakdash and Marusich in 2017).

This analysis reveals that volunteers treated with VAL201 display a statistically significant correlation for reductions over time in the amount of Testosterone and Prostate Specific Antigen ("PSA"), both of which are commonly-used markers for disease progression in prostate cancer.

The data further confirms that VAL201 has no statistically significant adverse trends across liver or kidney function. Furthermore, with no impact on cardiac rhythm in the patients either, this data further reinforces the continuation of the good safety and tolerability data emerging from the trial.

In addition to the independent analysis, the pharmacokinetics information collected from the clinical evaluation of ValiRx's more recent patients, shows that ValiRx is addressing the protocol's primary and secondary endpoints - as well as all the exploratory tertiary end points.
Further information about the endpoints is to be found posted on the NIH website, www.ClinicalTrials.gov, under: 'Dose Finding Safety Study of VAL201 in Cancer Patients (VAL201-001)'.

Prostate cancer therapeutics market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to reach a market value of USD 18.71 billion by 2027 while growing at a CAGR of 7.70% in the above-mentioned forecast period. Prostate cancer therapeutics market is growing due to factor such as increasing cases of prostate cancer and cardiovascular diseases.

https://thedailychronicle.in/news/1800254/prostate-cancer-therapeutics-market/

Regardless of buy or sell, it’s factored in by MM’s